Roche is putting 510 million dollars on the table, or around 420 million francs, to acquire the rights to a portfolio of antibody-drug conjugates (ADCs) developed by Hansoh Pharma. The Chinese group, based in Shanghai and described as a competitor of the Swiss giant, announced the transaction on 19 October 2026 in a press release relayed by the Keystone-ATS news agency. The amount committed upfront, however, represents only a small part of the deal’s headline value: most of it depends on future results, which have yet to be achieved.

A firm payment in two instalments

The transaction consists of a first payment of 400 million dollars on signing the contract, followed by a second of 110 million a year later. These 510 million make up the certain part of the deal: Roche will pay them whatever the outcome of the research.

The contract also provides for funding of up to 15 billion dollars, according to the press release cited by the agency. This amount is subject to the achievement of development, regulatory or commercial milestones. On top of this come royalties, of an unspecified amount, on any revenues.

Here it is necessary to distinguish fact from projection. The 510 million are a commitment; the 15 billion are a theoretical ceiling, which would only be reached if the molecules cleared the clinical stages, obtained approvals and found their market. This type of clause allows the buyer to limit its initial stake and pay more only in the event of success, while the seller retains a share of the potential.

Two possible readings of the deal

Depending on the figure chosen, the deal does not tell the same story. If one sticks to the firm amount, it is a measured bet for a group the size of Roche, which is buying options on early-stage molecules. If one looks at the maximum conditional amount, the deal appears to be a large-scale commitment to ADCs. Both readings can be defended, but the second assumes that everything succeeds, which is rarely the case in drug development. The available sources specify neither the number of molecules involved, nor their exact stage of development, nor the cancers targeted.

Who does what between Hansoh and Roche

The division of roles is clear. Hansoh retains control of the early stages of development, up to the completion of the first clinical phase. Roche then takes over worldwide, with the exception of mainland China, Hong Kong, Macau and Taiwan, where the rights remain with the Chinese group.

In practical terms, the Chinese partner conducts the earliest phase and Roche reserves the subsequent stages for itself, along with most of the markets outside this region. Where these later developments will take place, and whether they will involve teams in Switzerland, is not specified.

What antibody-drug conjugates are

ADCs, or antibody-drug conjugates, are preparations that combine, among other things, an antibody and a chemotherapy molecule. Their aim is to fight tumours.

Roche and Hansoh: a second deal in one year

This transaction is not the first between the two groups. Roche entered into business with Hansoh exactly one year earlier, acquiring the rights to the drug HS-20110 for an upfront payment of 80 million dollars. At the time, this product was the subject of a phase I clinical trial in China and the United States, against colorectal cancer and other cancers.

The comparison shows how things have evolved: a year ago, Roche paid 80 million for a single molecule; this time, the first payment reaches 400 million, five times as much, for an entire portfolio. The relationship is thus moving from a one-off test to a broader partnership.

Roche is also stepping up external licensing deals: the group recently in-licensed an experimental compound from Rona Therapeutics, this time in the field of obesity.

Why China? A question the source leaves open

The most interesting angle for the Swiss pharmaceutical industry, namely why its major groups are increasingly looking to China for their innovations, is not documented in the dispatch. It cites neither Roche’s motivations, nor the precise place of ADCs in its oncology strategy, nor the Swiss group’s reaction.

The context recalled by swissinfo.ch provides one element: a few days earlier, the outlet noted that a personalised cancer vaccine backed by Roche had stumbled, while other vaccines of this type were showing encouraging results in melanoma. Nothing, however, makes it possible to establish a link between this setback and the agreement with Hansoh.

For now, the facts come down to this: a Swiss pharmaceutical group is committing to pay 510 million dollars to a Chinese competitor for molecules in early development, with the prospect of much larger sums if the trials succeed. The next clinical stages will tell which of the two readings of the deal was the right one.

Sources

  • SWI swissinfo.ch: “Roche acquires Chinese antibody-drug conjugate rights for $500m”